ProCE Banner Activity


Acute Lymphoblastic Leukemia Discussion on the Use of Asparaginase Therapy in Young and Older Adults


Watch this on-demand webcast from a satellite symposium at ASH 2022 where an expert panel discusses the latest evidence on using pediatric-inspired asparaginase-based therapies to optimize the care of AYA and adult patients with ALL, including discussion of patient cases and practical guidance on strategies to increase completion of asparaginase treatment.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 30, 2023

Expiration: January 29, 2024

No longer available for credit.



Daniel J. DeAngelo

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Emily Curran

Emily Curran, MD

Assistant Professor
Department of Internal Medicine
Division of Hematology and Oncology
University of Cincinnati Cancer Center
Cincinnati, Ohio

Kjeld Schmiegelow

Kjeld Schmiegelow, MD, DMSci

Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from

Jazz Pharmaceuticals, Inc.

Target Audience

This program is intended for physicians and other healthcare professionals who care for adolescent/young adult and adult patients with acute lymphoblastic leukemia. 

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with ALL. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select, optimize, and apply asparaginase-containing regimens for adolescent/young adult and adult patients

  • Identify optimal methods of measuring and monitoring subclinical hypersensitivity or silent inactivation
  • Plan optimal approaches to achieve continued and active asparaginase treatment, including activity level testing and premedication

  • Integrate into practice expert recommendations and insights from available data on reexposure of asparaginase treatments or use of recombinant asparaginase formulations

  • Discuss recent clinical evidence and current recommendations for optimizing the therapeutic regimens for adolescent/young adult patients with ALL with pediatric-inspired protocols


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Daniel J. DeAngelo, MD, PhD: consultant/advisor/speaker: AbbVie, Agios, Amgen, Autolus, Blueprint, Forty-Seven, Gilead Sciences, GlycoMimetics, Incyte, Jazz, Kite, Novartis, Pfizer, Servier, Takeda; researcher: AbbVie, Blueprint, GlycoMimetics, Novartis; DSMB: Daiichi-Sanko, Fibrogen.

Emily Curran, MD: consultant/advisor/speaker: Amgen, Incyte, Kite, Pfizer, Servier, Tempus.

Kjeld Schmiegelow, MD, DMSci: consultant/advisor/speaker: Jazz, Servier; researcher: Novo Nordisk Foundation.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.



This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 26, 2023, through January 26, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.